HC Wainwright & Co. Maintains Buy on Heron Therapeutics, Lowers Price Target to $2

Benzinga Newsdesk www.benzinga.com Negative 74.4%

Neg 74.4% Neu 0% Pos 0%

HC Wainwright & Co. analyst Brandon Folkes maintains Heron Therapeutics (NASDAQ:HRTX) with a Buy and lowers the price target from $4 to $2.